Current Reports (8-K / 6-K)

Timothy Williams resigned from his role as Senior Vice President, General Counsel and Secretary, a key legal and corporate governance position.

Resignation is effective April 10, 2026, providing the company with a 12-day transition window following notification on March 29, 2026.

The filing states Williams is departing 'to pursue other endeavors', with no disclosure of disagreement, misconduct, or involvement in financial reporting issues.

EGM scheduled for April 29, 2026 at 10:30 AM Beijing time in Langfang City, Hebei Province.

Proposes increasing authorized share capital by US$317,200 to US$369,200, creating 317,200,000,000 additional Class A ordinary shares.

Record date: close of business April 3, 2026 (Cayman Islands time for shares, New York time for ADSs).

Board fully supports resolutions and recommends voting in favor.

ADS holders vote through JPMorgan Chase Bank, N.A.; each ADS represents 3,200 Class A ordinary shares.

EGM Notice and proxy forms available at https://ir.enaas.com.

Shareholders approved extending the business combination deadline from April 4, 2026, to December 4, 2026, allowing up to eight one-month extensions.

The Company must deposit $15,000 into the trust account for each monthly extension, funded via unsecured promissory notes.

Holders of 6,135 ordinary shares elected to redeem their shares, resulting in a $79,480.65 distribution from the trust account.

Following redemptions, approximately $4,762,484.24 remains in the trust account, with 2,545,432 ordinary shares outstanding.

The Third Amended and Restated Memorandum and Articles of Association and the Investment Management Trust Agreement were amended to reflect the extension terms.

Reverse stock split at 1-for-25 ratio approved by stockholders on August 7, 2025, and Board-fixed on March 20, 2026.

Effective at 12:01 a.m. ET on April 2, 2026; trading on Nasdaq under PSTV with new CUSIP 72941H806.

Outstanding shares reduced from ~171.6 million to ~6.86 million pre-split shares.

No fractional shares issued; cash payments provided in lieu based on fair market value.

Authorized shares unchanged at 200 million, increasing availability for issuance relative to outstanding shares.

Adjustments made to equity awards, warrants, and incentive plan share reserves proportionately.

ReNew Green received ~INR 8.83 billion (US$95 million) proceeds from LeapFrog-led consortium on April 2, 2026.

Consortium acquires 11.3% shareholding in ReNew Green.

ReNew Green's portfolio has 2.5 GW committed capacity for C&I customers, with over 2.0 GW commissioned.

~1.3 GW secured with long-term agreements from Microsoft, Amazon, and Google.

Additional 0.2 GW in C&I platform excluded from this transaction.

ReNew Green received ~INR 8.83 billion (US$95 million) proceeds from LeapFrog-led consortium on April 2, 2026.

Consortium acquires 11.3% shareholding in ReNew Green.

ReNew Green's portfolio has 2.5 GW committed capacity for C&I customers, with over 2.0 GW commissioned.

~1.3 GW secured with long-term agreements from Microsoft, Amazon, and Google.

Additional 0.2 GW in C&I platform excluded from this transaction.

2025 net income more than doubled to $40.8 million, reflecting structural improvements in underwriting and expense discipline.

Diluted EPS increased 95% to $2.88 and combined ratio improved to 75%, driving a 43% return on equity.

Company will enter California’s E&S homeowners market in Q2 2026, targeting <5% of 2026 premium with a 30% quota share for risk control.

California expansion is grounded in pricing sophistication (CA-specific Select product), claims execution, and a 30% expense ratio advantage.

Entry is deliberately incremental and reversible, with New York projected to remain >95% of 2026 premium and >80% through 2029.

BBB Foods Inc. filed its Annual Report on Form 20-F for fiscal year 2025 with the SEC on April 2, 2026.

The report includes the company's audited financial statements for the year ended December 31, 2025.

Investors can access the report on the company's investor website or the SEC's website.

Printed copies of the report are available free of charge upon request to the investor relations contact.

The company secured a new $400 million initial term loan maturing in April 2031, with interest rates of Term SOFR +5.00% or Base Rate +4.00%.

A $300 million delayed draw facility is available through August 2027, restricted to use for Permitted Acquisitions.

An uncommitted incremental facility of up to $500 million provides additional potential borrowing capacity.

The agreement requires the company to maintain minimum qualified cash of $50 million at each quarter-end.

All outstanding debt under the previous January 2023 credit agreement was repaid and terminated using proceeds from the new facility.

The FDIC and Pennsylvania Bureau terminated Consent Orders issued on May 15, 2025, against Quaint Oak Bank on March 30, 2026.

The Consent Orders were primarily related to the Bank's Bank Secrecy Act compliance program.

The Bank resolved the Consent Orders within approximately ten months through substantial enhancements to its compliance framework.

The remediation included financial crime management and third-party risk oversight improvements that strengthened the Company's control environment.

The Company's short-term financial performance was adversely affected by the significant resources dedicated to meeting the Consent Order requirements.

With remediation completed, the Company has resumed full focus on executing its strategic initiatives.

First quarter 2026 financial results will be released after market close on Tuesday, April 21, 2026.

Management will host a conference call to discuss results at 9:00 a.m. ET on Wednesday, April 22, 2026.

The call will be led by President and CEO Jeff Jackson and CFO Dan Weiss.

A webcast and dial-in details are provided for live access, with a replay available until May 6, 2026.

The Compensation Committee approved final FY2025 non-equity incentive plan payments for named executive officers.

CEO Charles E. Bradley, Jr.'s total compensation for FY2025 was $5,439,647, including a non-equity incentive payment of $3,283,500.

President & COO Michael T. Lavin's total FY2025 compensation was $1,386,590, with a non-equity incentive payment of $448,693.

EVP & CFO Danny Bharwani's total FY2025 compensation was $1,254,849, including a non-equity incentive payment of $479,808.

The CEO's incentive was based on seven weighted objectives totaling 720% of base salary, including budget, securitizations, originations, expenses, financing, contracts, and stock price targets.

Shareholders approved the issuance of shares for the merger with NorthWestern Energy, with 59.8 million votes for and 1.5 million against.

Shareholders approved increasing authorized shares from 100 million to 300 million, with 61.3 million votes for and 5.7 million against.

Shareholders approved changing the company name, with 65.1 million votes for and 1.8 million against.

Shareholders approved increasing authorized indebtedness from $8 billion to $20 billion, with 60.6 million votes for and 674,470 against.

The merger remains subject to federal and state regulatory approvals, with closing expected in the second half of 2026.

The combined company will be named Bright Horizon Energy Corporation and will serve customers across eight states.

Phillip Thomas is appointed Vice President, Controller and Chief Accounting Officer effective April 6, 2026 — a key finance leadership role overseeing financial reporting and controls.

Lori Bondar steps down as Chief Accounting Officer but remains Senior Vice President to support transition and plans to retire before fiscal year-end.

Thomas’ annual base salary is $360,574, with a target annual incentive of 55% of base salary and long-term incentive target of $175,000 (75% RSUs, 25% performance stock).

Thomas previously held the same role from July 2020 to December 2023 and has over 15 years of progressive finance leadership experience at Tyson.

Acquired Corstasis Therapeutics for $75M upfront cash, plus up to $180M in regulatory/commercial milestones and future royalty payments.

Amended existing credit facility to add $25M in term loans to fund the acquisition, with prepayment penalties for early repayment.

Sold $50M of future royalties from Otsuka collaboration to Athyrium, which will receive payments until $100M is collected before rights revert.

The acquisition adds Enbumyst, an FDA-approved nasal spray loop diuretic for edema, to Esperion's cardiovascular franchise.

Entered first amendment to Administrative Services Agreement dated February 2, 2026, effective March 30, 2026.

Sponsor or affiliate to provide office space at Unit OT 09-31, Central Park Towers, DIFC, Dubai for $20,000 monthly.

Accrued fees for February and March 2026 totaling $40,000 redirected to Sponsor Affiliate.

Services continue until six months post-IPO, business combination, or liquidation, extendable with working capital loans.

Sponsor and affiliate waive claims against the Trust Account.

Amendment attached as Exhibit 10.1.

Entered into a $100 million ATM sales agreement with AC Sunshine Securities LLC on March 31, 2026 — establishes flexible equity capital access mechanism.

Up to $70 million of shares will be offered under the April 2, 2026 ATM Prospectus Supplement to Form S-3 (File No. 333-281820) — confirms immediate regulatory eligibility for offerings.

Sales Agent receives 3.0% commission on gross proceeds and is reimbursed up to $100,000 for initial offering expenses — defines cost structure and upfront financial commitment.

Company retains full discretion over timing, price, and volume of sales via placement notices — no obligation to sell any shares, preserving strategic control.

Matthew Mo Kan Tsui appointed as Independent Director, bringing over 20 years of accounting and finance experience.

Mr. Tsui will serve as Chairman of the Audit Committee and member of both the Compensation and Nominating Committees.

Annual compensation for the directorship is set at HK$384,000, payable monthly.

Mr. Tsui qualifies as an independent director under Nasdaq Listing Rules and possesses requisite financial sophistication.

The appointment is formalized through a Director Offer Letter dated April 2, 2026, filed as Exhibit 10.1.

Shareholders approved a 2,000,000-share increase to the 2022 Equity Incentive Plan, raising total authorized shares to 7,000,000 — expanding dilution potential and equity compensation capacity.

A reverse stock split authorization (1-for-1.1 to 1-for-100) was approved, granting the Board discretion to implement it without further shareholder vote — signaling possible future compliance or market eligibility actions.

Five directors were elected, all receiving majority 'For' votes, though each faced significant 'Withheld' votes (372,794–550,006), indicating notable dissent among participating shareholders.

CBIZ CPAs P.C. was ratified as independent auditor with 6.84M 'For' votes, but 514,469 'Against' votes reflect meaningful auditor skepticism despite broker non-votes dominating the tally.

Re-appointment of co-founders Niels Riedemann (CEO) and Renfeng Guo (CSO) through 2030 confirms continuity in executive leadership and scientific strategy.

Board seeks extension of authority to acquire up to 10% of issued ordinary shares at ≤110% of 5-day average Nasdaq closing price — enabling flexible capital management.

Proposal to amend articles of association to increase authorized share capital supports future equity-based financing or compensation needs.

Approval of LTIP 2026 introduces a new long-term incentive plan, aligning executive and employee interests with shareholder value creation.

No dividend policy change: company reaffirms it has never paid cash dividends and does not anticipate doing so in the foreseeable future.

Hamilton Re agreed to maintain a Minimum Commitment Amount of the lesser of $1.8 billion or 60% of the Group's net tangible assets.

The new agreement replaces and supersedes the Prior Commitment Agreement dated July 1, 2023, as amended, effective April 1, 2026.

A two-tier withdrawal structure was established: Sub-Series A (excess capital) allows quarterly withdrawals with 55 days' notice.

Sub-Series B (capital at or below minimum) permits monthly withdrawals subject to a six-month notice requirement and monthly limits.

The Fund targets a Default Allocation of approximately 70% to equity strategies and 30% to macro strategies.

The Prior Commitment Agreement was terminated effective April 1, 2026, in connection with entering the new Investment Agreement.

Jacqueline D. Reses resigns as Class I director effective immediately after 2026 AGM on or around May 21, 2026.

Board size to reduce from nine to eight members contingent on Reses' resignation post-2026 AGM.

BCP requests substitution of Amit Dalmia for Amit Dixit as Blackstone Designee Class II director at 2026 AGM.

Dalmia nominated for Class II director term until 2029 Annual Meeting.

Neither resignation nor substitution due to disagreements with Company, management, or Board.

Proxy Statement to be filed around April 10, 2026 with Class II director election proposal.

Vericel awarded 10-year BARDA contract valued at up to $197 million for NexoBrid, effective April 1, 2026.

Base period of $35 million includes $10 million over next 12 months for initial NexoBrid procurement and VMI establishment.

Contract covers U.S. Strategic National Stockpile expansion, blast trauma indication development, U.S. manufacturing facility, and room temperature stable formulation.

NexoBrid is FDA-approved for enzymatic eschar removal in thermal burns, marketed in U.S., EU, Japan, and over 40 countries.

MediWound has not independently verified Vericel's BARDA contract information.

Amie Thuener O'Toole resigned as Vice President, Corporate Controller and Principal Accounting Officer, effective April 9, 2026.

Her resignation was voluntary and driven by pursuit of another professional opportunity, not any disagreement with the Company.

The role of Corporate Controller and Principal Accounting Officer is central to financial reporting integrity and SEC compliance.

No successor appointment or interim arrangement is disclosed in the filing.

Amie Thuener O'Toole resigned as Vice President, Corporate Controller and Principal Accounting Officer, effective April 9, 2026.

Her resignation was voluntary and driven by pursuit of another professional opportunity, not any disagreement with the Company.

The role of Corporate Controller and Principal Accounting Officer is central to financial reporting integrity and SEC compliance.

No successor appointment or interim arrangement is disclosed in the filing.

BD completed the spin-off of its Biosciences and Diagnostic Solutions business on February 9, 2026.

The spun-off business was combined with Waters Corporation as part of the transaction.

Exhibit 99.1 contains recast historical financials presenting the separated business as discontinued operations.

The recast provides a historical baseline for BD's standalone continuing operations.

Furnished financials include non-GAAP measures adjusting for separation, integration, and transaction costs.

Company sold 2,857,144 shares of common stock at a price of $0.70 per share for gross proceeds of approximately $2.0 million.

Investors received unregistered warrants to purchase 2,857,144 shares at an exercise price of $0.85, exercisable in six months.

H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee and warrants to purchase 142,857 shares.

Net proceeds are designated for working capital and general corporate purposes.

The Company suspended its existing At-the-Market (ATM) sales agreement prospectus effective April 1, 2026.

Acquired 80% of Tom Johnson Investment Management for $12.3 million, with $12 million paid in cash at closing.

TJIM manages approximately $1.63 billion in assets across equity and fixed income markets.

Principal seller retained 20% equity interest with put/call options exercisable after three years.

Richard H. Parry entered a new three-year employment agreement with TJIM as part of the transaction.

Transaction expected to provide TJIM with access to Bimini's public company infrastructure and capital markets expertise.

Audit Committee reduced from three to two members effective April 1, 2026, due to Mary Rotunno’s resignation, triggering non-compliance with Nasdaq Listing Rule 5605(c)(2).

Non-compliance does not affect current listing of VTGN common stock on The Nasdaq Capital Market.

Company is granted a cure period expiring earlier of next annual meeting or one year from April 1, 2026 — or 180 days if annual meeting occurs by September 28, 2026.

Board stated intent to regain compliance with Nasdaq Listing Rule 5605(c)(2) prior to cure period expiration.

2026 Annual Meeting set for June 11, 2026 at 8:30 a.m. Pacific Time at principal executive offices in Los Angeles.

Stockholders of record as of April 17, 2026 close of business entitled to notice and vote.

Deadline for stockholder proposals and director nominations is 5:00 p.m. Pacific Time on April 12, 2026.

Proposals must be submitted in writing to Corporate Secretary at 5005 McConnell Avenue, Los Angeles, CA 90066.

Meeting location or time may be adjusted by Board and specified in proxy statement.

Linda Pinne was promoted to CFO, effective April 1, 2026, from her prior role as Senior VP, Global Controller, and Chief Accounting Officer.

Her annual base salary is set at $385,000, establishing her fixed cash compensation.

She is eligible for a target annual cash bonus equal to 65% of her base salary, linking pay to performance.

She received a promotional grant of 10,647 RSUs, split evenly between service-based and performance-based awards.

The RSUs follow the same vesting and performance terms as the company's standard annual grants from February 2026.

Her existing employment and indemnification agreements remain in effect, providing continuity in her terms.

Rhone Resch appointed Chief Strategy Officer, a newly created role reporting to CEO Takahiko Onozuka.

Resch to focus on U.S. market expansion, global manufacturing footprint, and solar value chain partnerships.

Over 20 years solar experience, including CEO of Solar Energy Industries Association (2004-2016).

Employment agreement includes base salary, annual bonus targeted at percentage of base, and standard benefits.

Indemnification agreement provides protection for Resch as director/officer against proceedings.

Announcement dated March 31, 2026, via Exhibit 99.1 press release.

Propose carrying forward full EUR 6,901,677,892.10 balance sheet profit from 2025 financial year to new account.

Expand Supervisory Board from 6 to 8 members to enhance oncology, clinical development, and commercialization expertise amid strategic realignment.

Re-elect three current members (Helmut Jeggle, Prof. Dr. Anja Morawietz, Prof. Dr. Rudolf Staudigl) and elect two new (Dr. Susanne Schaffert, Prof. Dr. Iris Loew-Friedrich) to Supervisory Board.

Appoint EY GmbH & Co. KG as auditor and group auditor for 2026 financial year and interim reports through Q1 2027.

Cancel existing Authorized Capital 2025 (remaining EUR 113.8 million) and create new Authorized Capital 2026 up to EUR 129,513,743 until May 15, 2030, with subscription rights exclusions.

Reauthorize Management Board for virtual Annual General Meetings for two years post-registration.

Ms. Kapustina's employment ends on April 15, 2026 per Separation Agreement dated March 31, 2026.

Separation provides severance and benefits identical to her August 7, 2025 employment agreement.

Separation Agreement documented as Exhibit 10.1.

This is an 8-K/A amendment filing.

Stephen Hood appointed CEO effective March 27, 2026, via Motorsport Games Ltd with GBP 378,000 annual base salary and 50% target bonus.

Stanley Beckley appointed CFO effective March 27, 2026, with $300,000 annual base salary and 25% target bonus.

Hood reports to Board; Beckley reports to CEO and Board.

Hood's termination notice: 6 months by employee, 18 months by company or payment in lieu.

Beckley's severance: 6 months base salary without cause; accelerated equity vesting post-change in control.

Both subject to non-compete, non-solicit, and confidentiality covenants.

CEO Vlad Vitoc received a $312,610 one-time bonus for contributions to the recent capital raise — reflects direct linkage between executive compensation and financing success.

Head of Finance Jeffrey Himmelreich received a $50,000 one-time bonus — signals recognition of finance leadership in capital markets execution.

Bonuses were approved by the Board of Directors on March 27, 2026, and paid on March 31, 2026 — confirms timely, board-authorized compensation action.

Payment rationale is explicitly tied to the company’s recent capital raise — no other performance criteria or ongoing arrangements disclosed.

Verde Resources established Verde Resources Asia Pacific Pte. Ltd. as a wholly owned subsidiary on March 30, 2026.

The subsidiary is incorporated in Singapore and follows discussions with Singapore's Economic Development Board and Land Transport Authority.

The move advances the company's strategy to license its Net Zero Blueprint and related technologies globally.

Singapore will serve as the company's Asia Pacific headquarters for regional expansion.

The initiative is expected to support future generation and trading of carbon removal credits.

Revenues increased to RMB 206.0 million (US$29.5 million) for six months ended Dec 31, 2025, up RMB 59.6 million or 41% YoY.

Net income RMB 0.6 million (US$0.1 million) for H2 2025 vs net loss RMB 0.6 million prior year.

Acquired 51% of Zhonglian for RMB 25.5 million, paid RMB 8.2 million cash with RMB 17.3 million due by Oct 2026.

Cooperated with >3,100 B channels, securing >27 million end customers; partnered with >100 insurance companies.

Convertible notes: received net RMB 17.5 million proceeds; settled RMB 19.4 million principal/interest via shares and cash.

Total assets grew to RMB 283.1 million (US$40.5 million) as of Dec 31, 2025 from RMB 170.8 million.

Dr. Mark Erlander and James Levine stepped down January 26, 2026, as part of strategic review.

Separation agreements executed March 27, 2026, with 12-month base salary continuation: $635,000 for Erlander, $490,000 for Levine.

Erlander receives 2025 bonus $122,238, pro-rated 50% 2026 target bonus, 12-month healthcare, consulting agreement, options vesting to June 2026 then exercisable 12 months.

Levine receives 2025 bonus $61,740, pro-rated 50% 2026 target bonus, 12-month healthcare and options exercisability.

Erlander resigned as director effective March 27, 2026.

Both executives agreed to general release and confidentiality.

The company increased its revolving credit facility by $450 million to a total commitment of $850 million.

The amendment was executed on March 30, 2026, with Bank of America, N.A. as administrative agent.

The incremental commitments were arranged by BofA Securities, Inc., JPMorgan Chase Bank, N.A., and Truist Securities, Inc.

The amendment establishes new revolving credit commitments that increase the existing class of commitments.

The company incurred the $450 million in incremental commitments under specific sections of the existing credit agreement.

Kenneth E. Johnson stepping down as COO effective May 1, 2026.

Johnson to remain as senior advisor from May 1, 2026 until January 2027.

Transition announced on March 27, 2026.

No disagreement with Company on operations, policies, controls, or financial matters.

Smooth planned transition for key executive role.

Forward-looking statements include expected duration of COO transition.

Merger completed April 2, 2026; each TBHC share converted to 0.1993 Parent shares plus cash for fractions.

Company delisted from Nasdaq; trading suspended, Form 25 and Form 15 to be filed.

Parent contributed $30M cash to Company post-merger for debt repayment and general purposes.

Sixth Amendment to 2023 Credit Agreement permits merger; requires $10M loan prepayment.

Company charter amended to authorize 1,000 shares of $0.0001 par common stock.

Change of control occurred; Company now wholly owned subsidiary of Bed Bath & Beyond, Inc.

Geoff Race resigned as President and Mind-NRG Director effective March 31, 2026, via settlement agreement dated March 30, 2026.

Company to pay Race PILON of $529,610 salary, $15,888 pension, $66,201 pro-rated 2026 bonus, plus £30,000 severance.

Race's stock options fully vested with exercise extended to January 1, 2030; enters consultancy at £333/hour for min 35 hours/month from April 15, 2026 to April 14, 2027.

James O’Connor appointed Chief Business Officer and General Counsel effective April 21, 2026, by Board recommendation.

Press release furnished as Exhibit 99.1 highlights Race's 16-year contributions and O’Connor’s 20+ years life sciences experience.

Susan Ramirez appointed Principal Accounting Officer, adding to her role as First Vice President and Controller.

Ramirez's appointment effective April 2, 2026, with no change to her compensation.

Q1 2026 earnings call scheduled for April 27, 2026, at 8:30 a.m. PT/11:30 a.m. ET.

Earnings results for quarter ended March 31, 2026, to be released before the call.

Ramirez is a licensed CPA with prior experience at Summit Funding, Rabobank, and Mechanics Bank.

The company raised approximately $2.15 million in gross proceeds from a registered direct offering and private placement.

The offering consisted of 7,166,671 Class A shares at $0.30 per share, along with Series E and Series F warrants.

Proceeds are intended for general corporate purposes and working capital, supplementing existing cash.

The warrants were issued in a private placement under Regulation S to non-U.S. persons and are subject to resale restrictions.

A lock-up agreement restricts certain shareholders from selling securities for 60 days after a specified release date.

Silo Pharma acquired the 'QwikAgents' software and three domain names (qwikagents.com, qwikagents.ai, qwikagents.co) — a material asset purchase under Item 1.01.

Consideration consisted solely of 2,100,000 unregistered shares of Silo Pharma common stock, par value $0.0001, issued to Many Ads Inc.

The Agreement includes six-month survival of representations and warranties, with indemnification by the Seller for misrepresentations, third-party IP infringement, or gross negligence/fraud.

The Seller warranted exclusive ownership of the Software and Domain Names, confirmed no pending or threatened IP disputes, and disclosed use of one LGPL-licensed optional dependency.

Assignor agreed not to register or challenge any future 'qwikagents'-related domain names or trademarks, reinforcing Silo Pharma’s exclusive control over the brand.

Entered Forbearance Agreement on March 27, 2026, with Lender Frontwell Capital Partners covering Specified Defaults until April 27, 2026.

Outstanding Obligations under Credit Agreement: $16,116,215.30 as of March 25, 2026, at default interest rate.

Appointed Jeffrey T. Varsalone as CRO effective March 30, 2026, with broad authority superseding CEO.

Prohibits payments on $26.7M Blocked Notes held by Chairman, CEO affiliates, and former SPAC sponsor.

Imposed $600,000 reserve and $50,000 forbearance fee; increased Applicable Margins to 6.50% and 6.75%.

Must deliver satisfactory Refinancing Plan by April 9, 2026, or face termination of forbearance.

Entered Forbearance Agreement on March 27, 2026, with Lender Frontwell Capital Partners covering Specified Defaults until April 27, 2026.

Outstanding Obligations under Credit Agreement: $16,116,215.30 as of March 25, 2026, at default interest rate.

Appointed Jeffrey T. Varsalone as CRO effective March 30, 2026, with broad authority superseding CEO.

Prohibits payments on $26.7M Blocked Notes held by Chairman, CEO affiliates, and former SPAC sponsor.

Imposed $600,000 reserve and $50,000 forbearance fee; increased Applicable Margins to 6.50% and 6.75%.

Must deliver satisfactory Refinancing Plan by April 9, 2026, or face termination of forbearance.

The Trust declared a distribution of $1,955,000, or $0.170 per unit, payable April 24, 2026, to unitholders of record on April 15, 2026.

The net profits interest and the Trust will terminate on June 30, 2026, as the minimum production threshold has been met, with a final distribution expected around July 24, 2026.

The market price of Trust units is expected to decline to zero at termination, and the Trust may be unable to maintain NYSE listing compliance due to price declines, risking delisting to the OTC market.

For the payment period, net profits were $2,693,088, with $2,154,470 applicable to the Trust's 80% interest, and after expenses, $1,955,000 was available for distribution.

The United States District Court for the Northern District of Illinois preliminarily approved a settlement of stockholder derivative claims on March 19, 2026, resolving litigation without admission of wrongdoing.

The settlement requires Exicure to adopt and maintain specific corporate governance reforms outlined in Exhibit A to the Stipulation for at least four years.

Defendants' insurers will pay $675,000 in attorneys' fees and expenses to Plaintiffs' Counsel, subject to court approval, with service awards of up to $2,000 each for plaintiffs from that amount.

A final settlement hearing is scheduled for June 2, 2026, where the court will consider approval, and stockholders of record as of March 18, 2026, may object by May 12, 2026.

The derivative actions alleged breaches of fiduciary duties from January 7, 2021, through December 10, 2021, concerning internal controls and public statements about XCUR-FXN, which defendants denied.